Literature DB >> 32083675

Pharmacokinetics of once-daily doravirine over 72 h following drug cessation.

Xinzhu Wang1, Ana Milinkovic2, Branca Pereira2, Graeme Moyle2, Serge Fedele2, Lervina Thomas2, Dilek Yener2, Simon Connolly2, Myra McClure1, Marta Boffito1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32083675     DOI： 10.1093/jac/dkaa038

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  3 in total

Review 1.  Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data.

Authors:  Alexander E Rock; Jeremy Lerner; Melissa E Badowski
Journal:  HIV AIDS (Auckl)       Date:  2020-06-10

2.  Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study.

Authors:  Maria Mazzitelli; Melania Degli Antoni; Francesco Castelli; Diego Ripamonti; Gianluca Zuglian; Giuseppe Lapadula; Massimiliano Fabbiani; Alice Ferraresi; Cristina Putaggio; Anna Maria Cattelan; Eugenia Quiros-Roldan
Journal:  Medicine (Baltimore)       Date:  2022-07-29       Impact factor: 1.817

Review 3.  Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.

Authors:  Sauzanne Khalilieh; Ka Lai Yee; Rosa Sanchez; S Aubrey Stoch; Larissa Wenning; Marian Iwamoto
Journal:  Clin Drug Investig       Date:  2020-10       Impact factor: 2.859
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.